Donovan T Maust1,2,3, H Myra Kim2,3,4, Ilse R Wiechers5,6,7, Rosalinda V Ignacio1,2, Amy S B Bohnert2,3,8, Frederic C Blow1,2,3. 1. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan. 2. Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan. 3. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan. 4. Center for Statistical Consultation and Research, University of Michigan, Ann Arbor, Michigan. 5. Northeast Program Evaluation Center, Office of Mental Health and Suicide Prevention, Department of Veterans Affairs, West Haven, Connecticut. 6. Department of Psychiatry, University of California, San Francisco, San Francisco, California. 7. Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. 8. Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND/ OBJECTIVES: Benzodiazepines (BZDs) are widely prescribed to older adults. Although prescribing has declined in the U.S. Department of Veterans Affairs (VA), Medicare introduced BZD coverage in 2013. It is unknown whether declines in the VA have been widespread among older adults in the United States. DESIGN: Observational study in traditional fee-for-service Medicare, commercial insurance, and the VA. SETTING: United States, 2013-2017. PARTICIPANTS: Adults aged 55 and older in traditional Medicare (234,290,693 person-months), commercial insurance (337,827,125 person-months), and the VA (256,590,369 person-months). MEASUREMENTS: (1) Change in BZD and BZD-opioid co-prescribing modeled by Poisson regression over time; and (2) standardized ratios of BZD and BZD-opioid co-prescribing, using Medicare as the reference. RESULTS: From April 2013 to December 2017, the monthly percentage of adults aged 55 and older who received BZDs fell from 10.4% to 9.3% in Medicare, 6.6% to 6.5% in commercial insurance, and 5.7% to 3.0% in the VA. Monthly BZD-opioid co-prescribing over the same time fell from 4.0% to 3.0% in Medicare, 2.3% to 2.0% in commercial, and 2.2% to .6% for the VA. Age- and sex-adjusted rates of decline for BZD and BZD-opioid co-prescribing were statistically significant for all systems. Annual BZD rate reductions were .98 (Medicare), .99 (commercial), and .87 (VA; P < .001 for all); co-prescribing rate reductions were .95, .99, and .75 (P < .001 for all). Using standardized ratios accounting for demographic and clinical characteristics, both prescribing and co-prescribing were lowest for the VA relative to Medicare (standardized BZD ratio = .40; 95% confidence interval [CI] = .39-.40; standardized BZD-opioid co-prescribing ratio = .35; 95% CI = .35-.35). Prescribing in commercial insurance was also lower (BZD = .65; 95% CI = .65-.65; BZD-opioid co-prescribing = .65; 95% CI = .65-.65). CONCLUSION: BZD prescribing has declined much more to older adults receiving care through the VA than Medicare or commercial insurance. Other systems may learn from strategies implemented in the VA.
BACKGROUND/ OBJECTIVES: Benzodiazepines (BZDs) are widely prescribed to older adults. Although prescribing has declined in the U.S. Department of Veterans Affairs (VA), Medicare introduced BZD coverage in 2013. It is unknown whether declines in the VA have been widespread among older adults in the United States. DESIGN: Observational study in traditional fee-for-service Medicare, commercial insurance, and the VA. SETTING: United States, 2013-2017. PARTICIPANTS: Adults aged 55 and older in traditional Medicare (234,290,693 person-months), commercial insurance (337,827,125 person-months), and the VA (256,590,369 person-months). MEASUREMENTS: (1) Change in BZD and BZD-opioid co-prescribing modeled by Poisson regression over time; and (2) standardized ratios of BZD and BZD-opioid co-prescribing, using Medicare as the reference. RESULTS: From April 2013 to December 2017, the monthly percentage of adults aged 55 and older who received BZDs fell from 10.4% to 9.3% in Medicare, 6.6% to 6.5% in commercial insurance, and 5.7% to 3.0% in the VA. Monthly BZD-opioid co-prescribing over the same time fell from 4.0% to 3.0% in Medicare, 2.3% to 2.0% in commercial, and 2.2% to .6% for the VA. Age- and sex-adjusted rates of decline for BZD and BZD-opioid co-prescribing were statistically significant for all systems. Annual BZD rate reductions were .98 (Medicare), .99 (commercial), and .87 (VA; P < .001 for all); co-prescribing rate reductions were .95, .99, and .75 (P < .001 for all). Using standardized ratios accounting for demographic and clinical characteristics, both prescribing and co-prescribing were lowest for the VA relative to Medicare (standardized BZD ratio = .40; 95% confidence interval [CI] = .39-.40; standardized BZD-opioid co-prescribing ratio = .35; 95% CI = .35-.35). Prescribing in commercial insurance was also lower (BZD = .65; 95% CI = .65-.65; BZD-opioid co-prescribing = .65; 95% CI = .65-.65). CONCLUSION: BZD prescribing has declined much more to older adults receiving care through the VA than Medicare or commercial insurance. Other systems may learn from strategies implemented in the VA.
Authors: Richard C Oude Voshaar; Jaap E Couvée; Anton J L M van Balkom; Paul G H Mulder; Frans G Zitman Journal: Br J Psychiatry Date: 2006-09 Impact factor: 9.319
Authors: Donovan T Maust; Linda Takamine; Ilse R Wiechers; Frederic C Blow; Amy S B Bohnert; Julie Strominger; Lillian Min; Sarah L Krein Journal: Ann Fam Med Date: 2022 Jul-Aug Impact factor: 5.707
Authors: Lauren B Gerlach; Donovan T Maust; Helen C Kales; Myron Chang; H Myra Kim; Ilse R Wiechers; Kara Zivin Journal: Am J Psychiatry Date: 2022-05-26 Impact factor: 19.242
Authors: Camille P Vaughan; Ula Hwang; Ann E Vandenberg; Traci Leong; Daniel Wu; Melissa B Stevens; Carolyn Clevenger; Stephanie Eucker; Nick Genes; Wennie Huang; Edidiong Ikpe-Ekpo; Denise Nassisi; Laura Previl; Sandra Rodriguez; Martine Sanon; David Schlientz; Debbie Vigliotti; S Nicole Hastings Journal: BMJ Open Qual Date: 2021-11
Authors: Lianlian Lei; Julie Strominger; Ilse R Wiechers; H Myra Kim; Frederic C Blow; Amy S B Bohnert; Lillian Min; Sarah L Krein; Donovan T Maust Journal: J Gen Intern Med Date: 2021-05-28 Impact factor: 6.473